Showing 3061-3070 of 5956 results for "".
- Bausch + Lomb Receives FDA Clearance For Ultra Multifocal For Astigmatism Contact Lenseshttps://modernod.com/news/bausch-lomb-receives-fda-clearance-for-ultra-multifocal-for-astigmatism-contact-lenses/2476156/Bausch + Lomb announced that it has received FDA 510(k) clearance for Bausch + Lomb Ultra Multifocal for Astigmatism contact lenses, the company’s first multifocal toric lens to be available as a standard offering. Bausch + Lomb says the monthly silicone hydrogel lens is the company&
- Alcon’s Phaco Development (PD) Program Celebrates 10 Yearshttps://modernod.com/news/alcons-phaco-development-pd-program-celebrates-10-years/2476164/The Phaco Development (PD) program, an initiative between Alcon and specialist training institutes that builds cataract surgical capabilities across Asia and Russia, is celebrating its 10th anniversary this year. Over th
- Bausch + Lomb Announces Exclusive Agreement with Modulight to Develop New Photodynamic Laserhttps://modernod.com/news/bausch-lomb-announces-exclusive-agreement-with-modulight-to-develop-new-photodynamic-laser/2476166/Bausch + Lomb and Modulight, a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s Visudyne (verteporfin for injection)
- Ocular Therapeutix Announces FDA Approval of Dextenza for the Treatment of Ocular Pain Following Ophthalmic Surgeryhttps://modernod.com/news/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery/2476171/Ocular Therapeutix announced that the FDA has approved Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- Recipients of the 2018 OWL Awards Recognized for Advancing Diversity in Ophthalmology Leadershiphttps://modernod.com/news/recipients-of-the-2018-owl-awards-recognized-for-advancing-diversity-in-ophthalmology-leadership/2479662/OWL: Advancing Diversity in Leadership (OWL) announced the winners of the 2018 OWL Awards at the organization’s Signature Event, which was held October 28 in Chicago during the annual meeting of the American Academy of Ophthalmology (AAO 2018). OWL presents the awards each year to those who best
- Johnson & Johnson Vision Announce $26.35 Million Collaboration for Prevention and Treatment of Myopiahttps://modernod.com/news/johnson-johnson-vision-announce-26-35-million-collaboration-for-prevention-and-treatment-of-myopia/2479677/The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI), and Johnson & Johnson Vision announced a $26.35 million research collaboration to tackle myopia. By 2050, half of the world’s population are projected to be myopic, with one billion expected to have high my
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p